EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Granzyme B in Autoimmune Skin Disease

Anna Gleave iD, David J Granville iD

Biomolecules · 18.02.2023 · 13 (2) · 388

DOI: 10.3390/biom13020388 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biomolecules, online erschienen am 18.02.2023. Verfasst von Anna Gleave und 1 weiteren Autor:innen. Beteiligte Einrichtung: British Columbia Professional Firefighters' Burn and Wound Healing Laboratory, International Collaboration On Repair Discoveries (ICORD) Centre, Vanc…. Hauptthemen laut MEDLINE: Alopecia Areata, Pemphigoid, Bullous, Vitiligo, Autoimmune Diseases. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 131 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CIHR, Michael Smith Foundation for Health Research, Cancer Research Society.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Autoimmune diseases often present with cutaneous symptoms that contribute to dysfunction, disfigurement, and in many cases, reduced quality-of-life. Unfortunately, treatment options for many autoimmune skin diseases are limited. Local and systemic corticosteroids remain the current standard-of-care but are associated with significant adverse effects. Hence, there is an unmet need for novel therapies that block molecular drivers of disease in a local and/or targeted manner. Granzyme B (GzmB) is a serine protease with known cytotoxic activity and emerging extracellular functions, including the cleavage of cell–cell junctions, basement membranes, cell receptors, and other structural proteins. While minimal to absent in healthy skin, GzmB is markedly elevated in alopecia areata, interface dermatitis, pemphigoid disease, psoriasis, systemic sclerosis, and vitiligo. This review will discuss the role of GzmB in immunity, blistering, apoptosis, and barrier dysfunction in the context of autoimmune skin disease. GzmB plays a causal role in the development of pemphigoid disease and carries diagnostic and prognostic significance in cutaneous lupus erythematosus, vitiligo, and alopecia areata. Taken together, these data support GzmB as a promising therapeutic target for autoimmune skin diseases impacted by impaired barrier function, inflammation, and/or blistering.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alopecia AreataPemphigoid, BullousVitiligoAutoimmune DiseasesHumansGranzymes

Stichwörter der Autor:innen

Granzyme Bautoimmune skin diseaseextracellular matrixinflammationserine proteasesmall molecule inhibitor

Substanzen

Granzymes

Autor:innen und Institutionen

  • British Columbia Professional Firefighters' Burn and Wound Healing Laboratory, International Collaboration On Repair Discoveries (ICORD) Centre, Vancouver Coastal Health Research Institute, University of British Columbi…
  • Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC V6T 1Z7, Canada.

ORCID-Profile: Anna Gleave, David J Granville

Förderung

  • CIHR
  • Michael Smith Foundation for Health Research
  • Cancer Research Society
  • Eczema Society of Canada
  • Mitacs
  • Praxis Spinal Cord Institute
  • LEO Foundation
  • Canadian Institutes of Health Research

Zitieren

APA

Gleave, A., & Granville, D. J. (2023). Granzyme B in Autoimmune Skin Disease. Biomolecules, 13(2), 388. https://doi.org/10.3390/biom13020388

Vancouver

Gleave A, Granville DJ. Granzyme B in Autoimmune Skin Disease. Biomolecules. 2023;13(2):388. doi:10.3390/biom13020388

BibTeX
@article{Gleave2023,
  author = {Gleave, Anna and Granville, David J},
  title = {Granzyme B in Autoimmune Skin Disease},
  journal = {Biomolecules},
  year = {2023},
  volume = {13},
  number = {2},
  pages = {388},
  doi = {10.3390/biom13020388}
}
Kostenlos starten →